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Hispanic (55.0%), enrolled in fee-for-service program (83.1%) and from an urban 
region (60.1%). OM-related antibiotic prescription claims decreased from 137,557 
in 2008 ($5,281,040) to 65,697 in 2011 ($2,010,391). The mean cost per prescription 
decreased significantly from $38.39 in 2008 to $30.60 in 2011 (p< 0.01). The most 
frequently used category of OM-related antibiotics was penicillins (215,654 claims). 
Amoxicillin was the most frequently prescribed OM-related antibiotic (48.2%), fol-
lowed by cefdinir (21.0%). However, the total outpatient prescription cost was highest 
for cefdinir ($5,736,640), followed by amoxicillin-clavulanate ($2,798,234), amoxi-
cillin ($1,914,929), azithromycin ($1,298,427), cefuroxime ($49,191), clarithromycin 
($42,959), cefpodoxime ($19,685) and ceftriaxone ($5,792). Higher age, Asian race/ 
ethnicity, female gender, fee-for-service program enrollment, Texas region, acute 
OM, amoxicillin-clavulanate, and cephalosporins were significant predictors 
(p< 0.01) of high cost prescriptions. ConClusions: Prescription claims and expen-
ditures for selected OM-related antibiotics declined between 2008 and 2011 in the 
Texas Medicaid pediatric population.
SyStemic DiSorDerS/conDitionS – clinical outcomes Studies
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objeCtives: No randomised controlled trial has compared voriconazole and posa-
conazole directly for prophylaxis against invasive fungal infections (IFI) in high risk 
haematology patients. We performed a systematic review and indirect comparison 
of voriconazole versus posaconazole using itraconazole/fluconazole as the common 
comparator. Methods: Systematic review of full body of evidence including ran-
domised controlled trials and non-randomised studies. Adjusted indirect meta-anal-
ysis was performed using Bucher method. Non-randomised studies provide evidence 
for direct comparison between voriconazole and posaconazole. Results: A total of 
4 RCTs and 4 non-randomised studies that evaluated voriconazole or posaconazole 
were included. In these studies, two risk groups were identified on the basis of disease 
type – the haemopoetic stem cell transplant (HSCT) at risk of GVHD population, and 
acute myelogenous leukaemia or myelodysplastic syndrome (AML/MDS) population. 
The indirect estimates of risk differences (RD) were not statistically significantly dif-
ferent from 0.0; therefore indicating that voriconazole is not worse than posaconazole 
in terms of the incidence of proven or probable IFI [RD (95% CI): 0.00 (-0.06, 0.06) in 
HSCT/GVHD; 0.04 (-0.06, 0.14) in AML/MDS] and all-cause mortality rates [RD (95% 
CI): -0.00 (-0.07, 0.06) in HSCT/GVHD; 0.03 (-0.09, 0.16) in AML/MDS]. Results should be 
interpreted with caution due to heterogeneity between the risk levels of patient popu-
lations. However, the robustness of the indirect comparisons can be supported by the 
four direct non-randomised studies which consistently demonstrated similar efficacy 
of voriconazole and posaconazole and superior efficacy of voriconazole over itracona-
zole and fluconazole based on the incidence of breakthrough IFI. ConClusions: 
The clinical evidence presented in the direct and indirect comparisons consistently 
demonstrate that there are no statistically significant differences between voricona-
zole and posaconazole in terms of efficacy outcomes. Voriconazole offers an alterna-
tive option to posaconazole, which is the only therapy currently reimbursed on the 
Australian Pharmaceutical Benefits Schedule for prophylaxis of IFI.
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objeCtives: To define interchangeability of locally produced Paracetamol 
(Acetaminophen INN), 500mg tablets. Methods: For this purpose Paracetamol 
500mg tablets produced by 7 local manufacturers were tested. As a comparator 
product was used Panadol 500mg, produced by GlaxoSmithKline. Bioequivalence 
testing was done according to the WHO guideline, Multisource (generic) pharma-
ceutical products: guidelines on registration requirements to establish interchange-
ability, WHO Technical Report Series, No.937, 2006. Based on Biopharmaceutics 
Classification System Paracetamol tablets bioequilvalency testing was done in vitro 
through determination of dissolution. Results: In each media of pH 1.2, 4.5 and 
6.8 were tested 12 unit samples. All samples were dissolved in three media in not 
less than 85% of the labelled amount of the paracetamol in 15 minutes. According to 
the questionnaire, all manufacturers producing Paracetamol tablets answered that 
the formulation of dosage form was considered the attribute of active pharmaceu-
tical ingredient and excipients and used machinery’s specification. As criteria for 
choosing the formulation, manufacturers were used pharmacopoeial monograph, 
stability study data and dissolution results. Mongolian manufacturer’s Paracetamol 
formulations not contain excipients such as sodium bicarbonate, which is fasten-
ing the drug absorption. Three manufacturers use Povidone as a binder, same like 
comparator product. Most formulations contain Talc and Magnesium stearate as 
a lubricant mix, when comparator contains Stearic acid and Talc. All formulations 
contain starch and cellulose, their derivates. ConClusions: Paracetamol 500mg 
tablets produced by all 7 local manufacturers: LM1, LM2, LM3, LM4, LM5, LM6 and 
LM7 have dissolution more than 85% in 15 minutes in each of three media. Therefore 
the dissolution profile comparison with an f2 test is unnecessary [4]. Samples: LM1, 
LM2, LM3, LM4, LM5, LM6 and LM7 are bioequivalent and could be interchangeable 
with comparator pharmaceutical product.
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manaGement of overweiGht
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cept and infliximab showed the ICER of 6,719,775 baht/QALY compared to usteki-
numab. The probability of cost-effective at threshold of 120,000 baht/QALY remained 
in favor of ustekinumab at 72.60% and presented at 13.60% for both etanercept 
and infliximab. ConClusions: Ustekinumab seems to be more cost-effective than 
etanercept and infliximab for patients with moderate-to-severe plaque psoriasis 
following biologic treatment guideline for psoriasis in Thailand.
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objeCtives: The aim of the study was to identify adherence and predicting fac-
tors for non-adherence and to assess the association of adherence with patient 
satisfaction of glaucoma therapy. Methods: The study population included 1,046 
glaucoma outpatients with less than two years of drug use recruited at15 eye clinics 
from March to November 2013. All patients completed a self-administered question-
naire asking about their daily use of glaucoma medications to estimate adherence 
and patients’ baseline characteristics to examine predicting factors for non-adher-
ence. Adherence was defined as patients administering the drug for ≥ 90% of pre-
scribed days. Patient satisfaction was also measured using the 14-item Treatment 
Satisfaction Questionnaire for Medication (TSQM) questionnaire which provided 
scores on four sub-scales: medication effectiveness, side effects, convenience and 
global satisfaction. The scores on TSQM are ranged 0 to 100 where higher scores indi-
cate better satisfaction. Results: Of 1,046 patients, 71.1%showed to be adherent to 
their glaucoma therapy while 28.9% accounting for 298 number of patients remained 
non-adherent. The predicting factors for non-adherence were found to be patients 
age < 65 years, and employed (p< 0.05). Non-adherent patients showed less satisfac-
tory to treatment than adherent patients as displayed by relatively lower scores in 
all sub-scales on TSQM. In the scores on the TSQM, the largest difference between 
non-adherent and adherent patients was observed on medication effectiveness 
(26.07±12.21 vs. 59.21±14.27, p< 0.001) and the smallest difference was detected in 
side effects (89.53±18.00 vs. 90.50±16.46, p= 0.405). ConClusions: About one third 
of the study population were non-adherent, and age and employment status were 
shown to influence non-adherence. Patient satisfaction was significantly associ-
ated with adherence given the lower scores on TSQM in non-adherent patients. 
Thus, these findings should be taken into account in decision making process for 
glaucoma treatment.
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objeCtives: To elicit utility values of adult myopic patients in mainland 
China. Methods: A valid sample of 442 myopia patients (spherical equivalent at 
least −0.5 D) aged 17–44 years, who were scheduled to undergo refractive surgery, 
were recruited. Information on time trade-off (TTO, years of life willing to sacrifice 
for treatment of myopia) and standard gamble (SG) for blindness (risk of blindness 
from therapy, willing to sacrifice for treatment of myopia) utility values, socio-
demographic and clinical data were obtained. Results: The mean utility values 
based on TTO and SG were 0.96±0.05 (95% confidence interval (CI) 0.95–0.96, median 
0.98) and 0.93±0.09 (95% CI 0.92–0.94, median 0.97), respectively. Myopic patients 
using contact lens had significantly higher TTO utility values than those wearing 
glasses (P< 0.001). There was no significant difference in the TTO and SG utility val-
ues by age, gender, occupation, educational levels, residence, reasons for refractive 
surgery, severities and duration of myopia (P> 0.05). ConClusions: The TTO and SG 
produce similar mean utility values, but there is poor agreement between results for 
individuals from the two methods. Utility values associated with myopic patients 
obtained in this study or reported in the literature appear to be higher than those 
obtained for other ophthalmic conditions.
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objeCtives: To determine the prescribing patterns and expenditures for otitis 
media (OM)-related antibiotics in the Texas Medicaid pediatric population, and 
identify the demographic and antibiotic-related factors associated with expen-
sive prescriptions for OM-related antibiotics. Methods: This retrospective study 
used Texas Medicaid outpatient medical and prescription claims data for children 
younger than 13 years old with a diagnosis of OM (ICD-9: 381.0-382.0) and claims 
for OM-related antibiotics from January 2008 to December 2011. OM-related anti-
biotics were selected based on the guidelines proposed by the American Academy 
of Pediatrics and the American Academy of Family Physicians in 2004, and were 
classified into three categories: cephalosporins, macrolides and penicillins (amox-
icillin, amoxicillin-clavulanate). The total number (proportion) of prescriptions 
and costs were compared across selected antibiotics and categories. Generalized 
linear model was used to evaluate potential factors associated with expensive 
prescriptions. Results: 335,638 children with a mean age of 3.9 (SD= 3.2) years 
were included. The majority were boys (52.1%), younger than 3 years old (55.0%), 
